Response: Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy [3]

Journal of the National Cancer Institute

Volumn 99, Issue 13, 2007, Pages 1051-1052

  Hershman, Dawn ^a   Neugut, Alfred I ^a   Grann, Victor ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REDUCTION; EPIDEMIOLOGICAL DATA; HEALTH INSURANCE; HUMAN; LETTER; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MEDICARE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION EXPOSURE; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

EID: 34547789306     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm016     Document Type: Letter

References (4)

1. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007;99:196-205.
2. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9.
3. Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005;97:1724-33.
4. Le Deley MC, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007;25:292-300.